Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Receivables (2016 - 2025)

Integra Lifesciences Holdings' Receivables history spans 17 years, with the latest figure at $285.7 million for Q4 2025.

  • For Q4 2025, Receivables rose 2.58% year-over-year to $285.7 million; the TTM value through Dec 2025 reached $285.7 million, up 2.58%, while the annual FY2025 figure was $285.7 million, 2.58% up from the prior year.
  • Receivables for Q4 2025 was $285.7 million at Integra Lifesciences Holdings, up from $267.1 million in the prior quarter.
  • Across five years, Receivables topped out at $288.0 million in Q2 2025 and bottomed at $230.0 million in Q1 2021.
  • The 5-year median for Receivables is $260.8 million (2023), against an average of $259.5 million.
  • The largest YoY upside for Receivables was 27.46% in 2021 against a maximum downside of 9.25% in 2021.
  • A 5-year view of Receivables shows it stood at $243.2 million in 2021, then grew by 12.47% to $273.6 million in 2022, then decreased by 1.84% to $268.6 million in 2023, then rose by 3.71% to $278.5 million in 2024, then grew by 2.58% to $285.7 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Receivables are $285.7 million (Q4 2025), $267.1 million (Q3 2025), and $288.0 million (Q2 2025).